Exact Sciences Co. (NASDAQ:EXAS) is Thompson Investment Management Inc.’s 6th Largest Position

Thompson Investment Management Inc. increased its position in Exact Sciences Co. (NASDAQ:EXAS) by 17.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,774 shares of the medical research company’s stock after acquiring an additional 36,505 shares during the quarter. Exact Sciences comprises approximately 2.0% of Thompson Investment Management Inc.’s holdings, making the stock its 6th biggest position. Thompson Investment Management Inc.’s holdings in Exact Sciences were worth $13,585,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Huntington National Bank increased its holdings in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after acquiring an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new position in Exact Sciences in the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP bought a new position in Exact Sciences in the 3rd quarter worth approximately $35,000. Vestor Capital LLC bought a new position in Exact Sciences in the 3rd quarter worth approximately $46,000. Finally, V Square Quantitative Management LLC bought a new position in Exact Sciences in the 3rd quarter worth approximately $47,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Stock Down 1.4 %

Shares of EXAS opened at $53.53 on Friday. The company has a market cap of $9.91 billion, a PE ratio of -45.75 and a beta of 1.24. The business has a fifty day moving average of $57.31 and a 200 day moving average of $60.04. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Insider Buying and Selling

In related news, CEO Kevin T. Conroy purchased 19,500 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was bought at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. This represents a 1.85 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.36% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on EXAS shares. BTIG Research upped their price target on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Robert W. Baird dropped their price target on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Stifel Nicolaus dropped their price target on Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Citigroup dropped their price target on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein increased their target price on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $72.76.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.